HCPCS Level II code Q5130 designates an injection of pegfilgrastim-pbbk (Fylnetra), a biosimilar granulocyte colony-stimulating factor supplied in 0.5 mg units. This code captures administration of a biologic used to prevent or treat chemotherapy-induced neutropenia, an important component of supportive oncology care. Nationally, accurate coding of biosimilar injections affects clinical reporting, payer coverage determinations, and drug utilization monitoring.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what Q5130 represents clinically and operationally, common billing modifiers associated with injectable biologics, and expected sites of service where the product is administered. The publication also summarizes benchmark topics readers should expect: reimbursement coding alignment for biosimilars, payer coverage policy considerations, and clinical context for pegfilgrastim biosimilar use.

This piece is designed for billing professionals, oncology clinic administrators, and policy analysts seeking a clear reference on code purpose, payer relevance, and the practical elements that affect billing and care delivery for pegfilgrastim-pbbk injections at the national level.